Laser Treatment for Normal Tension Glaucoma

Overseen By Lauren Nguyen

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Ngoc Nguyen Inc.

Disqualifiers: Angle closure glaucoma, Intraocular surgery, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 day

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to evaluate the efficacy of direct selective laser trabeculoplasty (DSLT) or laser treatment in Asian patients with normal tension glaucoma. The main question it aims to answer is:

Does the DSLT reduce intraocular pressure (IOP) and medication use in Asian NTG subjects? Participants will attend routine follow-up visits with their eye surgeon and glaucoma testing such as optical coherence tomography (OCT) imaging and visual field test(s) after the laser study treatment.

Are You a Good Fit for This Trial?

This trial is for Asian individuals with normal tension glaucoma, a condition where the eye's pressure is normal but there's still damage to the optic nerve. Participants should be willing to undergo routine follow-ups and tests like OCT imaging and visual field assessments after receiving laser treatment.

Inclusion Criteria

Central corneal thickness (CCT) 450-600µm

Asian descent

All participants are able to provide written informed consent before participation

Exclusion Criteria

I had eye surgery over a year ago, except for vision correction.

I expect to have cataract surgery during the study.

I have glaucoma, but not normal-tension glaucoma.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Direct Selective Laser Trabeculoplasty (DSLT) using the BELKIN Vision Eagle device

1 day

1 visit (in-person)

Follow-up

Participants attend routine follow-up visits with their eye surgeon and undergo glaucoma testing such as OCT imaging and visual field tests

12 months

Multiple visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Direct Selective Laser Trabeculoplasty (DSLT)

Trial Overview

The study is testing Direct Selective Laser Trabeculoplasty (DSLT), a type of laser therapy, to see if it can lower eye pressure and reduce the need for medication in patients with normal tension glaucoma without causing significant discomfort or side effects.

How Is the Trial Designed?

Group I: DSLT Treatment Arm Experimental Treatment 1 Intervention

Participants will receive Direct Selective Laser Trabeculoplasty (DSLT) using the BELKIN Vision Eagle device. The procedure is performed without a contact lens and delivers non-contact laser energy to the trabecular meshwork to lower intraocular pressure. All participants undergo standard pre- and post-procedure evaluations, including IOP measurements, visual field testing, and OCT imaging.

Who Is Running the Clinical Trial?

Ngoc Nguyen Inc.

Lead Sponsor

Alcon Research

Industry Sponsor

Trials

739

Recruited

128,000+

Raquel C. Bono

Alcon Research

Chief Medical Officer since 2022

MD from Harvard Medical School

David Endicott

Alcon Research

Chief Executive Officer since 2018

MBA from University of Southern California